



PTO/SB/08B (08-03)  
Approved for use through 7/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT




(Use as many sheets as necessary)

SHEET 1 of 5

### Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467

### NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	AA	SHEPPARD, G. S. '3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists' <i>Journal Of Medicinal Chemistry</i> vol. 37, no. 13, 2011-2032, 1994	<input type="checkbox"/>	
	AB	KWONG, F. Y & BUCHWALD, S. L. 'A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols' <i>Org. Lett.</i> Vol. 4, no. 20, 3517-3520, 2002.	<input type="checkbox"/>	
	AC	DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissenschaften' Database Accession No. 8172403	<input type="checkbox"/>	
	AD	DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissenschaften' Database Accession No. 183150, reaction 2 of 4	<input type="checkbox"/>	
	AE	DATABASE CROSSFIRE BEILSTEIN 'Beilstein institute zur foerderung der chemischen wissenschaften' Database Accession No. 5433848	<input type="checkbox"/>	
	AF	MONGE A ET AL 'New indole and pyridazinoindole analogs – synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation' <i>Archiv Der Pharmazie</i> vol. 328, no. 10, pp. 689-698, 1995.	<input type="checkbox"/>	
	AG	ALEKSANDRZAK, K. McGOWN, A. T & HADFIELD, J. A. 'Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4' <i>Anti-Cancer Drugs</i> vol. 9, pp.545-550, 1998.	<input type="checkbox"/>	
	AH	McGOWN, A. T. & FOX, B. W. 'Structural and biochemical comparison of the anti-mitotic agents colchicines, combretastatin A4 and amphetinile' <i>Anti-Cancer Drug Design</i> vol. 3, pp. 249-254, 1989.	<input type="checkbox"/>	
	AI	GALBRAITH, S. M ET AL. 'Effects of combrestatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo' <i>Anti-Cancer Research</i> vol. 21, pp. 93-102, 2001.	<input type="checkbox"/>	
	AJ	BOLTON, D ET AL 'Synthesis and potential anxiolytic activity of 4-amino-pyrido[2,3-b]indoles' <i>Bioorganic &amp; Medicinal Chemistry Letters</i> vol. 3, no. 10, pp. 1941-1946, 1993.	<input type="checkbox"/>	
Examiner Signature			Date Considered	2/9/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 2 of 5

### Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US


### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MB	AK	BLACKBURN, T. P. '11-amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, a novel GABA <sub>A</sub> modulator with Potential anxiolytic activity' <i>Bioorganic &amp; Medicinal Chemistry Letters</i> vol. 4, no. 2, pp. 279-284, 1994.	<input type="checkbox"/>
	AL	McGOWN, A, T ET AL 'Pre-clinical studies of a novel anti-mitotic agent, amphethinile' <i>Br J Cancer</i> vol. 57, pp. 157-159, 1988.	<input type="checkbox"/>
	AM	McGOWN, A, T. & FOX, B, W. 'Interaction of the novel agent amphethinile with tubulin' <i>Br J Cancer</i> vol. 59, pp. 865-868, 1989.	<input type="checkbox"/>
	AN	NEWELL, D, R ET AL 'Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics' <i>British Journal of Cancer</i> vol. 81(5), pp. 760-768, 1999.	<input type="checkbox"/>
	AO	DARK, G, G. 'Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature' <i>Cancer Research</i> vol. 57, pp. 1829-1834, 1997.	<input type="checkbox"/>
	AP	PLAYER, M, R & SOWELL, J, W. 'Synthesis of 1,3-disubstituted-2-amino-5-hydroxyindoles by reductive aromatization' <i>J Heterocyclic Chem</i> vol. 30 (125), pp. 125 - 128, 1993.	<input type="checkbox"/>
	AQ	HESS, S ET AL. '7-deazaadenines bearing polar substituents: structure-activity relationships of new A <sub>1</sub> and A <sub>3</sub> adenosine receptor antagonists' <i>J Med Chem</i> vol. 43, pp. 4636-4646, 2000.	<input type="checkbox"/>
	AR	FUSE, E ET AL 'Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity' <i>Journal of the National Cancer Institute</i> vol. 86, no. 13, 1994.	<input type="checkbox"/>
	AS	EGER, K ET AL 'Synthesis of substituted indoles and pyrimido[4,5-b]indoles by dehydration of tetrahydroindoles and tetrahydropyrimidoindoles' <i>Liebigs Ann Chem</i> pp. 465-470, 1993.	<input type="checkbox"/>
	AT	KEGLEVIC, D & GOLES, D 'Indole compounds. VI. Syntheses of indole thioethers by direct cyclization of phenylhydrazine hydrochlorides and aliphatic acetals under mild conditions' <i>Croatica Chemica Acta</i> vol. 42, pp. 513-521, 1970.	<input type="checkbox"/>
MB	AU	DESATY, D ET AL 'The synthesis of N-acetylserotonin' <i>Biochem Biophys Acta</i> vol. 62, pp. 179-180, 1962.	<input type="checkbox"/>
	AV	MASHIMA, H & MATSUMURA, M. 'Roles of external ions in the excitation-contraction coupling of frog skeletal muscle' <i>Japan J Physiol</i> vol. 12, pp 639-653, 1962.	<input type="checkbox"/>
Examiner Signature			Date Considered 2/9/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 3 of 5

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MB	AW	HEATH-BROWN, B & PHILPOTT, P. G. 'Studies in the indole series. Part 1. Indolylalkylamines' <i>J Chem Soc</i> pp. 7165-7078, 1965.	<input type="checkbox"/>
	AX	DESAI, H. K. & USGAONKAR, R. N. 'Isocoumarins. Part 1. Synthesis of 4-Methylisocoumarins' <i>Jour Indian Chem Soc</i> vol. 41, no. 12, pp. 821 - 829, 1964.	<input type="checkbox"/>
	AY	HEACOCK, R. A. & HUTZINGER, O. 'The preparation of the hydroxyskatoles and 5,6-dihydroxyskatole' <i>Canadian Journal of Chemistry</i> vol. 42, pp. 514 - 521, 1964.	<input type="checkbox"/>
	AZ	MA, J, C, N & WARNHOFF, E. W. 'On the use of nuclear magnetic resonance for the detection, estimation and characterization of N-methyl groups' <i>Canadian Journal of Chemistry</i> vol. 43, pp. 1849 - 1869, 1965.	<input type="checkbox"/>
	BA	BENIGNI, J, D & MINNIS, R. L. 'The synthesis of 5,6-dihydroxyindole and some of its derivatives (1)' <i>J Heterocyclic Chem</i> vol. 2, pp. 387 - 392, 1965.	<input type="checkbox"/>
	BB	MARCHAND, B ET AL 'Preparative chemistry of indole compounds. 1. Preparation of phenylhydrazones of pyruvic acid esters from methylloxalacetic esters and diazonium salts and conversion of these compounds into indole-2-carboxylic esters' <i>J Prakt Chem</i> vol. 13, pp. 54-57, 1961. +English Abstract	<input type="checkbox"/>
	BC	TABORSKY, R, G: & DELVIGS, P. 'Synthesis of some substituted tryptophols of possible physiological importance and a study with 3-(2-acetoxyethyl)-5-methoxyindole (5-methoxytryptophol O-acetate) on sexual maturation' <i>J Med Chem</i> vol. 9, pp. 251 - 254, 1966.	<input type="checkbox"/>
	BD	TABORSKY, R, G ET AL '6-hydroxyindoles and the metabolism of melatonin' <i>J Med Chem</i> vol. 8(6), pp 855-858, 1965.	<input type="checkbox"/>
	BE	TABORSKY, R, G ET EL 'Synthesis and preliminary pharmacology of some 1-methylindoles' <i>J Med Chem</i> vol. 8(4), pp. 460 - 466, 1965.	<input type="checkbox"/>
MB	BF	ARUTYUNYAN, G. S. ET AL 'Relations between chemical structure and pharmacological activity of 5-alkoxytryptamines' <i>Farmakol Toksikol</i> vol. 27(6), pp. 681 - 686, 1964. +English Abstract	<input type="checkbox"/>
Examiner Signature			Date Considered 2/9/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 4 of 5

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
5/10/06 AB	BG	KRASNYKH, P, G ET AL 'Radioprotective action of 5-methoxytryptamine and other alkoxytryptamines' <i>Radiobiologiya</i> vol. 2(1), pp. 156-160, 1962. +English Abstract	<input type="checkbox"/>
AB	BH	SHAGALOV, N, P. ET AL 'Indole derivatives. XXI. Synthesis of 4- and 6-chloroindolybutyric acids' <i>Zh Obshch Khim</i> vol. 34(5), pp. 1592 - 1595, 1964. +English Abstract	<input type="checkbox"/>
AB	BI	KEGLEVIC, D ET AL 'The synthesis of 3,5-disubstituted indoles by cyclization under mild conditions' <i>Croat Chem Acta</i> vol. 33, pp. 83-88, 1961. +English Abstract	<input type="checkbox"/>
AB	BJ	GREENBERG, A, J. & KETCHAM, R 'Determination of urinary indolic metabolites' <i>Journal of Pharmaceutical Sciences</i> vol. 67(4), pp. 478 - 480, 1978.	<input type="checkbox"/>
AB	BK	COTTERILL ET AL 'Cyclopropamitosenes, Novel Bioreductive Anticancer Agents. Synthesis, Electrochemistry, and Biological Activity of 7-Substituted Cyclopropamitosenes and Related Indolequinones' <i>J Med Chem</i> vol.37(22), pp. 3834 - 3843, 1994	<input type="checkbox"/>
AB	BL	COTTERILL ET AL 'Cyclopropamitosenes, Novel Bioreductive Anticancer Agents. Synthesis, 7-Methoxycyclopropamitosene and Related Indolequinones', <i>Tetrahedron</i> vol. 50(25), pp. 7657 - 7674, 1994.	<input type="checkbox"/>
AB	BM	MOODY ET AL 'Synthesis and Biological Activity of Thiazolylindolequinones, Analogues of the Natural Product BE 10988', <i>J Med Chem</i> vol. 38(6), pp. 1039 - 1043, 1995.	<input type="checkbox"/>
AB	BN	MOODY ET AL 'Synthesis and Cytotoxic of Thiazolyl Indolequinones', <i>Anti-Cancer Drugs</i> vol. 10, pp. 577 - 589, 1999.	<input type="checkbox"/>
AB	BO	CHIKVAIDZE ET AL 'Soobshch Akad Nauk Gruz' Bulletin of the Academy of Sciences of Georgia, vol. 141(3), pp. 545-548, 1991. +English Abstract	<input type="checkbox"/>
AB	BP	BESWICK ET AL 'The Synthesis of 4 - Substituted Indoles via Arenetricarbonylchromium(0) Complexes' <i>Tetrahedron</i> vol. 44(23), pp. 7325 - 7334, 1988.	<input type="checkbox"/>
AB	BQ	NECHVATAL & WIDDOWSON 'A New Synthesis of 4-Substituted Indoles via Tricarbonylarenechromium(0) Complexes' <i>J Chem Soc Chem Commun</i> vol. 8, pp. 467-468, 1982.	<input type="checkbox"/>
AB	BR	DICKENS ET AL 'Transition Metal Medicated Thiation of Aromatic Rings' <i>Tetrahedron</i> vol. 47(40), pp. 8621 - 8634, 1991.	<input type="checkbox"/>
AB	BS	FUKUDA ET AL 'Directed C-7 Lithiation of 1-(2,2-Diethylbutanoyl)indoles' <i>Tetrahedron</i> vol. 55(20), pp. 9151 - 9162, 1999.	<input type="checkbox"/>
Examiner Signature			Date Considered 2/9/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)  
Approved for use through 7/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/509633
Filing Date	February 18, 2005
First Named Inventor	ARNOULD, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100467-1 US

SHEET 5 of 5

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BT	ALEXANDRZAK ET AL 'Antimitotic Activity of Diaryl Compounds with Structural Features Resembling Combretastatin A-4' <i>Anticancer Drugs</i> vol. 9(6), pp. 545-550, 1998.	<input type="checkbox"/>
	BU	MCGOWAN & FOX 'Structural and Biochemical Comparison of the Anti-Mitotic Agents Colchicine, Combretastatin A4 and Amphelthinile' <i>Anticancer Drug Des</i> vol. 3(4), pp. 249-254, 1989.	<input type="checkbox"/>
	BV	MCGOWAN & FOX 'Interaction of the Novel Agent Amphethinile with Tubulin', <i>British Journal of Cancer</i> vol. 59(6), pp. 865 – 868, 1989.	<input type="checkbox"/>
	BW	MCGOWAN & FOX 'Pre-Clinical Studies of a Novel Anti-Mitotic Agent, Amphethinile' <i>British Journal of Cancer</i> vol. 57(2), pp. 157 – 159, 1988.	<input type="checkbox"/>
	BX	GAIRNS ET AL 'Synthesis of Fused 1 $\lambda$ <sup>4</sup> ,2-Thiazines(2-Azathiabenzenes)' <i>J Chem Soc Perkin Trans</i> vol. 1(3), pp. 483 – 489, 1986.	<input type="checkbox"/>
	BY	ALLEN 'Synthesis of Indole-2-Carboxylic Acid Esters', <i>Synth Commun</i> vol. 29(3), pp. 447 – 455, 1999.	<input type="checkbox"/>
	BZ	DUNAN & ANDRAKO 'Synthesis of 2-(N,N-Dialkylaminomethyl)-7-Phenylthioindoles', <i>J Pharm Sci</i> vol. 57(6), pp. 979 – 983, 1968.	<input type="checkbox"/>
	CA	SOMEI & NATSUME 'Photochemical Rearrangements for the Synthesis of 3-,4- and 6-Substituted Indoles', <i>Tetrahedron Lett</i> vol. 27, pp. 2451 – 2454, 1973.	<input type="checkbox"/>
	CB	MIRZIASHVILI ET AL <i>Khim Geterotsikl Soedin</i> vol. 1, pp. 54 – 56, 1991. +English Abstract	<input type="checkbox"/>
	CD	NERENBERG ET AL 'Radioimmunoassay of Oxfendazole in Bovine, Equine, or Canine Plasma or Serum', <i>J Pharm Sci</i> vol. 67(11), pp. 1553 – 1557, 1978.	<input type="checkbox"/>
	CE	CHIKVAIDZE ET AL 'New Indole Derivatives: Synthesis and Antibacterial Activity' <i>Pharmaceutical Chemistry Journal</i> , Vol. 32, No. 1, pp.30-33, 1998	<input type="checkbox"/>
	CF	MCCORMICK ET AL 'Characterization and Synthesis of a New Calcium Antagonist from the Venom of a Fishing Spider', <i>Tetrahedron Lett</i> vol. 49, No. 48, pp. 11155-11168, 1993	<input type="checkbox"/>
	CG	CHIKVAIDZE ET AL 'Indole Derivatives 138.* Synthesis of Some New Sulfur-Containing Derivatives of Indole', <i>Chem Heterocycl Compd</i> , Vol. 27 No. 11 pp. 1218-1221, 1991	<input type="checkbox"/>
Examiner Signature			Date Considered 2/9/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

# Fax Cover Sheet

Date: 09 May 2006

To:	From: Nyeemah Grazier
Application/Control Number: 10/509,633	Art Unit: 1626
Fax No.: 781-839-4121	Phone No.: (571) 272-8781
Voice No.: 781-839-4693	Return Fax No.: (703) 872-9306
Re:	CC:

☐ Urgent ☐ For Review ☐ For Comment ☐ For Reply ☒ Per Your Request

Comments:

Per your request the IDS submitted on June 28, 2005, namely reference citation number "BG" has been considered.

Number of pages 8 including this page

## STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450